Dong-A ST Co., Ltd. (KRX:170900)

South Korea flag South Korea · Delayed Price · Currency is KRW
49,350
+900 (1.86%)
At close: Mar 6, 2026
6.53%
Market Cap 451.98B
Revenue (ttm) 770.63B
Net Income (ttm) -514.77M
Shares Out 9.16M
EPS (ttm) -41.77
PE Ratio n/a
Forward PE 11.90
Dividend 686.27 (1.42%)
Ex-Dividend Date Mar 10, 2026
Volume 29,510
Average Volume 33,162
Open 48,500
Previous Close 48,450
Day's Range 47,500 - 49,450
52-Week Range 40,900 - 59,200
Beta 0.45
RSI 39.95
Earnings Date Feb 9, 2026

About Dong-A ST

Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Clofazimine cap. For lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bladder, and ovarian cancers; Gonadopin inj./PFS for infertility and anovulation; Growtropin II inj./AQ /cartridge to treat growth failure due to an inad... [Read more]

Sector Healthcare
Founded 1932
Employees 1,679
Stock Exchange Korea Stock Exchange
Ticker Symbol 170900
Full Company Profile

Financial Performance

Financial Statements

News

Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA

– Global Market Expansion Accelerates with Back-to-Back FDA and EC Authorizations SEOUL, South Korea — Dong-A ST (CEO: Jeong Jae-hoon, KRX: 170900) proudly announces that its Stelara biosimilar, IMULD...

1 year ago - Financial Post

US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®

Dong-A ST’s biologics license application (BLA) for Imuldosa, submitted in October 2023, is approved by the U.S. Food and Drug Administration SEOUL, South Korea — Dong-A ST (President/CEO Jae-Hun Jung...

1 year ago - Financial Post

US FDA Approves Dong-A ST's IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®

Dong-A ST's biologics license application (BLA) for Imuldosa, submitted in October 2023, is approved by the U.S. Food and Drug Administration Dong-A ST (President/CEO Jae-Hun Jung, KRX: 170900) announ...

1 year ago - Benzinga